Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
GH Research ( (GHRS) ) just unveiled an update.
On January 31, 2025, GH Research PLC announced a forthcoming update on its Phase 2b trial for GH001, aimed at treating treatment-resistant depression (TRD). The company plans to host a conference call and webcast on February 3, 2025, to discuss data from the double-blind, placebo-controlled study. The trial follows promising results from a previous study where 87.5% of TRD patients achieved rapid remission using GH001, highlighting its potential to revolutionize TRD treatment.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on the development of novel therapies for psychiatric and neurological disorders. The company’s primary product is GH001, a mebufotenin-based treatment designed for patients with treatment-resistant depression (TRD), administered through a proprietary inhalation method.
YTD Price Performance: 22.50%
Average Trading Volume: 77,526
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $504.2M
See more data about GHRS stock on TipRanks’ Stock Analysis page.
